Core Alternative Capital’s Bristol-Myers Squibb BMY Stock Holding History

Core Alternative Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.7K	Hold	620	–	–	0.01%	157
2026 Q1	$37.6K	Hold	620	–	–	0.01%	153
2025 Q4	$33.4K	Sell	620 -80	-11%	-$3.85K	0.01%	155
2025 Q3	$31.6K	Hold	700	–	–	0.01%	147
2025 Q2	$32.4K	Hold	700	–	–	0.01%	148
2025 Q1	$42.7K	Hold	700	–	–	0.01%	137
2024 Q4	$39.6K	Hold	700	–	–	0.01%	152
2024 Q3	$36.2K	Hold	700	–	–	0.01%	155
2024 Q2	$29.1K	Hold	700	–	–	0.01%	171
2024 Q1	$38K	Sell	700 -992	-59%	-$50.5K	0.01%	158
2023 Q4	$86.8K	Sell	1,692 -2,088	-55%	-$110K	0.01%	137
2023 Q3	$219K	Sell	3,780 -68	-2%	-$4.17K	0.03%	115
2023 Q2	$246K	Buy	3,848 +8	+0.2%	+$536	0.04%	90
2023 Q1	$266K	Sell	3,840 -179	-4%	-$12.6K	0.04%	84
2022 Q4	$289K	Buy	4,019 +2,653	+194%	+$200K	0.04%	93
2022 Q3	$97K	Buy	1,366 +66	+5%	+$4.79K	0.02%	110
2022 Q2	$100K	Buy	1,300 +180	+16%	+$13.7K	0.02%	116
2022 Q1	$82K	Buy	1,120 +674	+151%	+$45.3K	0.02%	123
2021 Q4	$28K	Buy	446 +97	+28%	+$5.69K	0.01%	128
2021 Q3	$21K	Buy	+349	New	+$23K	﹤0.01%	90

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Core Alternative Capital's BMY Position: Q2 2026 in Review

Core Alternative Capital held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 620 shares worth $35.7K. The position accounts for 0.01% of the portfolio, ranked #157.

Core Alternative Capital first reported a position in BMY in Q3 2021 and has held it in 20 quarters since. The position peaked at $289K in Q4 2022. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Core Alternative Capital held 620 shares of Bristol-Myers Squibb worth $35.7K as of Q2 2026.
Core Alternative Capital left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.01% of Core Alternative Capital's portfolio in Q2 2026, its #157 holding.
Core Alternative Capital first reported a position in Bristol-Myers Squibb in Q3 2021 and has held it in 20 quarters since.
Core Alternative Capital's Bristol-Myers Squibb position peaked at $289K in Q4 2022.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Core Alternative Capital's 13F filing for Q2 2026, filed 14 Aug 2026.